{"id":25976,"date":"2025-11-06T10:17:25","date_gmt":"2025-11-06T09:17:25","guid":{"rendered":"https:\/\/porib.com\/?p=25976"},"modified":"2026-01-14T14:29:36","modified_gmt":"2026-01-14T13:29:36","slug":"rodriguez-lago-i-munoz-nunez-f-lucendo-aj-de-lossada-juste-a-cabez-a-de-la-cuadra-grande-a-oyaguez-i-monte-boquet-e-2","status":"publish","type":"post","link":"https:\/\/porib.com\/en\/rodriguez-lago-i-munoz-nunez-f-lucendo-aj-de-lossada-juste-a-cabez-a-de-la-cuadra-grande-a-oyaguez-i-monte-boquet-e-2\/","title":{"rendered":"Rodr\u00edguez-Lago I, Mu\u00f1oz N\u00fa\u00f1ez F, Lucendo AJ, De Lossada Juste A, Cabez A, de la Cuadra-Grande A, Oyag\u00fcez I, Monte-Boquet E"},"content":{"rendered":"<div class=\"miniatura_foto\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-13915 alignleft\" src=\"https:\/\/porib.com\/wp-content\/uploads\/2021\/07\/Pharmaco-Open.jpg\" alt=\"\" width=\"90\" height=\"120\" \/><\/div>\n<p style=\"text-align: justify;\"><strong>Rodr\u00edguez-Lago I, Mu\u00f1oz N\u00fa\u00f1ez F, Lucendo AJ, De Lossada Juste A, Cabez A, de la Cuadra-Grande A, Oyag\u00fcez I, Monte-Boquet E<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h6 style=\"text-align: justify;\">Cost-Effectiveness Analysis of Etrasimod compared with Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain<\/h6>\n<h6 style=\"text-align: justify;\"><strong>Pharmacoecon Open. 2025. doi: 10.1007\/s41669-025-00619-6<\/strong><\/h6>\n<div class=\"col80p\">\n<p style=\"text-align: justify;\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41241890\/\">M\u00c1S INFORMACI\u00d3N<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rodr\u00edguez-Lago I, Mu\u00f1oz N\u00fa\u00f1ez F, Lucendo AJ, De Lossada Juste A, Cabez A, de la Cuadra-Grande A, Oyag\u00fcez I, Monte-Boquet E &nbsp; &nbsp; Cost-Effectiveness Analysis of Etrasimod compared with Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain Pharmacoecon Open. 2025. doi: 10.1007\/s41669-025-00619-6 M\u00c1S INFORMACI\u00d3N<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"quote","meta":{"footnotes":""},"categories":[116,919,305],"tags":[],"class_list":["post-25976","post","type-post","status-publish","format-quote","hentry","category-ace-acu-tipo-de-proyecto","category-enfermedades-autoinmunes","category-pharmacoeconomics-open","post_format-post-format-quote"],"translation":{"provider":"WPGlobus","version":"2.10.3","language":"en","enabled_languages":["es","en"],"languages":{"es":{"title":true,"content":true,"excerpt":false},"en":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/25976"}],"collection":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/comments?post=25976"}],"version-history":[{"count":4,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/25976\/revisions"}],"predecessor-version":[{"id":26084,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/posts\/25976\/revisions\/26084"}],"wp:attachment":[{"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/media?parent=25976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/categories?post=25976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porib.com\/en\/wp-json\/wp\/v2\/tags?post=25976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}